17 March 2023
EMA/CHMP/85734/2023 Rev.1
Human Medicines Division

Committee for medicinal products for human use (CHMP)

PROM[1] agenda for the meeting on 20 March 2023

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

20 March 2023, 09:00–16:00, virtual meeting

Disclaimers

Some of the information contained in this document is considered commercially confidential or sensitive and therefore not disclosed.

Of note, agendas and minutes are working documents primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

[1] The CHMP PROM is a meeting to discuss CHMP organisational matters and other topics in preparation for the CHMP Plenary meeting. It is a virtual meeting, which usually takes place on Monday before the CHMP Plenary meeting. CHMP members, working party chairs and national experts together with EMA staff are participating in this forum. Depending on the nature of the issue and availability of documents and experts some PROM topics can be discussed at the CHMP Plenary.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Agenda and Minutes

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PROM meeting to be held on 20 March 2023. As the PROM is a preparatory meeting for the CHMP plenary session, restrictions and declarations of interests applicable to the items in the draft agenda of the upcoming CHMP plenary session are also considered. See March 2023 PROM minutes.

1.2. Adoption of agenda

CHMP PROM agenda for 20 March 2023 meeting.

1.3. Adoption of the minutes

CHMP PROM Minutes of 20 March 2023 meeting will be adopted at the March 2023 CHMP plenary.

2. Quality Domain

2.1. Biologics Working Party (BWP)

Chair: Sean Barry

2.1.1. Agenda and Minutes

- Agenda for the BWP meeting to be held by Webex on 20-22 March 2023
- Minutes of the BWP meeting held by Webex on 16-18 January 2023

Action: For information

2.1.2. Call for nomination for the BWP Vice-Chair

Following the election of Sean Barry as the new BWP Chair last month, the position of Vice-Chair is now vacant. Candidates are kindly asked to submit a brief CV in support of their candidature together with a cover letter highlighting their expertise. Nominations should be sent to the Agency by 12 April 2023.

The election will take place at the April 2023 CHMP plenary meeting.

Action: For information

2.2. Quality Working Party (QWP)

Chair: Blanka Hirschlerova, Vice-Chairs: Marie-Hélène Sabinotto, Laivi Saaremäe

2.2.1. Agenda and Minutes

- Final agenda and minutes for QWP-CT meeting held virtually on 15 February 2023
- Final agenda for QWP meeting held F2F on 6-8 March 2023
- Final minutes of 102nd QWP meeting held virtually on 21–23 November 2022

Action: For information

2.2.2. Extension of the mandate of Vice-Chair (human)

The current mandate of the QWP human vice-Chair Ms Laivi Saaremael (EE) is expiring in April 2023.

Action: For adoption

2.3. Biosimilar Medicinal Product Working Party (BMWP)

Chair: vacant, Vice-Chair: Niklas Ekman

2.3.1. Agenda and Minutes

- Final agenda from the TC held on 8 March 2023 and minutes from the meeting held virtually on 23 November 2022

Action: For information

2.3.2. Call for nomination for the BMWP Chair

Following the expiry of mandate of Elena Wolff-Holz, the position of BMWP Chair is vacant. Candidates are kindly asked to submit a brief CV in support of their candidature together with a cover letter highlighting their expertise. Nominations should be sent to the Agency by 12 April 2023.

The election will take place at the April 2023 CHMP plenary meeting.

Action: For information

2.3.3. Nomination of new BMWP members

Nomination of 3 new BMWP members to replace those members who resigned in December 2022.

Action: For endorsement

2.4. Quality Innovation Group (QIG)

No topics

2.5. Formulation Expert Group (FEG)

No topics

3. Non-Clinical Domain

3.1. Non-Clinical Working Party (NcWP)

Chair: Susanne Brendler-Schwaab, Vice-Chair: Karen van Malderen

3.1.1. Agenda and minutes

- Draft minutes for the NcWP meeting held virtually on 14-15 February 2023
- Draft agenda for the NcWP meeting to be held virtually on 21-22 March 2023

Action: For information

3.1.2. Bisphenol A (BPA) EMA-EFSA joint document on divergent opinion (Art. 59)

EFSA has carried out a re-evaluation of risks to public health related to the presence of bisphenol A (BPA) in foodstuffs. EFSA has suggested lowering the tolerable daily intake (TDI) for BPA from 4 µg/kg bw to 0.2 ng/kg bw. During the public consultation EMA provided comments highlighting diverging views related to various aspects of the EFSA scientific assessment. No agreement was achieved and in line with Art. 59 of EMA founding regulations, EFSA and EMA have therefore drafted a joint document for the European Commission to outline the divergencies.

Action: For adoption

3.1.3. Mandate, objectives and rules of procedure for the Non-clinical and new approach methodologies European Specialised Expert Community (ESEC)

Presentation of the mandate of the Non-clinical and new approach methodologies European Specialised Expert Community (ESEC).

Action: For endorsement

3.1.4. Call for nominations - Non-clinical and new approach methodologies ESEC

Following the re-organisation of the EMA Working Parties and the creation of the Non-Clinical Domain, EMA is launching the Non-Clinical (NC) and New Approach Methodologies (NAMs) European Specialised Expert Community (ESEC). The European Medicines Agency "Regulatory Science Strategy to 2025" clearly identifies the development as well as the use, where possible and appropriate, on innovative and 3Rs-compliant non-clinical methods as a strategic goal both for the human and veterinary medicines regulatory network.

CHMP Committee members are invited to nominate non-clinical experts with special knowledge and experience and/or strong interest in the areas of: innovative *in vitro* models such as 3D-cell culture models, organoids, microphysiological systems (MPS), alternative testing models for reproductive toxicology, human cell-based systems including those using iPSCs, *in vitro-in vivo* extrapolation (IVIVE), in silico and read-across methods, alternatives to the use of animals in batch release testing, qualification and/or validation and regulatory acceptance of NAMs and 3Rs principles implemented in *in vivo* studies.

Experts should be part of the European Regulatory Network (e.g. assessors working for a NCA, members of the different WPs or experts from academia in institutions/universities with relevant knowledge in the area of Non-Clinical and New Approach Methodologies).

Action: for information

3.1.5. CMDh questions to NcWP on new nitrosamines

The CMDh requests that the NcWP determines the acceptable intake for:

- N-nitroso-perindopril
- N-nitroso-labetalol
- N-nitroso-benazepril
- N-nitroso-lisinopril

based on lifetime daily exposure including information on the points of departure and methodology used.

Action: For adoption

3.1.6. Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'

The excipients drafting group (ExcpDG) finalised the report on proline following the public consultation. It was endorsed by the NcWP and the EC Notice to Applicants group.

Action: for adoption

3.1.7. Revision of the 'SWP recommendations on the duration of contraception following the end of treatment with a genotoxic drug' (EMA/CHMP/SWP/74077/2020)

Following a request from Medicines for Europe, CMDh requested NcWP some clarifications related to genotoxic medicinal products and contraception duration period. The NcWP response to CMDh was endorsed by CHMP in February 2023. As a follow up, the SWP published paper needed to be revised.

NcWP Chair: Susanne Brendler-Schwaab

Action: For endorsement

3.1.8. Steering committee of the International Consortium for Innovation and Quality in Pharmaceutical Development

Proposal to have Susanne Brendler-Schwaab (chair of the NcWP) representing CHMP/EMA at the steering committee of IQ MPS to explain the new structure of the non-clinical domain at EMA, give a summary of the 3 years workplan, and provide information on the relevant contact points and ways to approach EMA, also in relation to seek advice and to follow the way of regulatory acceptance of MPS/new approach methodologies. The workshop will take place on 3 April 2023.

Action: For endorsement

3.1.9. CHMP request to NcWP on new nitrosamines

CHMP requests that the NcWP determines the acceptable intake for the following nitrosamines based on lifetime daily exposure including information on the points of departure and methodology used.

- N-nitroso-vildagliptin

Action: For adoption

3.2. Joint 3Rs Replacement, Reduction and Refinement Working Party (3Rs)

Chair: Sonja Beken, Vice-Chair: Sarah Adler-Flindt

3.2.1. Agenda and Minutes

- Adopted minutes of the 3RsWP meeting held virtually on 23 November 2022
- Final agenda for the 3RsWP stakeholder hybrid meeting held on 28 February–01 March 2023

Action: For information

4. Methodology Domain

4.1. Methodology Working Party (MWP)

Chair: Kit Roes, Vice-Chair: Kristin Karlsson

4.1.1. Presentation of the mandate, objectives and rules of procedure for the European Specialised Expert Community (ESEC) for Methodology

Presentation of the mandate of the Methodology European Specialised Expert Community (ESEC).

Action: For endorsement

4.1.2. Nomination of Methodology ESEC experts

Nomination by MWP of the experts to enter the Methodology European Specialised Expert Community (ESEC).

Action: For endorsement

4.1.3. Nomination of Modelling & Simulation Operational Expert Group (MSOEG)

Nomination by MWP of the experts to enter the Modelling and Simulation Operational Expert Group (MSOEG).

Action: For endorsement

4.1.4. Nomination of Biostatistics Operational Expert Group (BSOEG)

Nomination by MWP of the experts to Biostatistics Operational Expert Group (BSOEG).

Action: For endorsement

4.1.5. Agenda and Minutes

- Final Agenda and Minutes for MWP meetings held by teleconference on 2 February 2023, 16 February 2023 and 2 March 2023.

Action: For information

4.2. Pharmacokinetics Working Party (PKWP)

Chair: Carolien Versantvoort

4.2.1. Product-specific guidelines

Draft product-specific guidelines for release for 3-month public consultation

- Lurasidone film-coated tablets, 18.5, 37 and 74 mg product-specific bioequivalence guidance (EMA/39336/2023)
- Bosutinib film-coated tablets, 100, 400 and 500 mg product-specific bioequivalence guidance (EMA/590937/2022)
- Metformin immediate-release film-coated tablets 500, 850 and 1000 mg product-specific bioequivalence guidance (EMA/591346/2022)
- Fampridine prolonged-release tablet 10 mg product-specific bioequivalence guidance (EMA/39346/2023)
- Pirfenidone film-coated tablets 267, 537 and 801mg and hard capsules 267mg product-specific bioequivalence guidance (EMA/901584/2022)

Action: For adoption

5. Clinical Domain

5.1. Central Nervous System Working Party (CNSWP)

Chair: Andre Elferink, Vice-Chair: Ewa Balkowiec Iskra

5.1.1. Establishment of CNS European Specialised Expert Community

Adoption of mandate and call for nominations.

Action: for endorsement

5.2. Cardiovascular Working Party (CVSWP)

Chair: Alar Irs, Vice-Chair: Patrick Vrijlandt

5.2.1. Nomination of Cardiovascular ESEC experts

Nomination by CVSWP of experts to enter the Cardiovascular European Specialised Expert Community (ESEC).

Nomination(s) received

Action: For endorsement

5.3. Oncology Working Party (ONCWP)

Chair: Pierre Demolis, Vice-Chair: Olli Tenhunen

5.3.1. Nomination of Oncology ESEC experts

Nomination by ONCWP of experts to enter the Oncology European Specialised Expert Community (ESEC).

Nomination(s) received

Action: For endorsement

5.3.2. Update of the Oncology ESEC

Presentation on the activities of the Oncology ESEC nearly 1 year implementation.

Action: For discussion

5.4. Rheumatology and Immunology Working Party (RIWP)

No topics

5.5. Infectious Disease Working Party (IDWP)

No topics

5.6. Vaccines Working Party (VWP)

No topics

5.7. Haematology Working Party (HaemWP)

Chair: Daniela Philadelphy

5.7.1. Establishment of the Haematology European Specialised Expert Communities

Adoption of mandate and call for nominations.

Action: For adoption

5.7.2. Agenda

- Agenda of the Blood cluster TC held on 10 March.

Action: For information

5.8. Scientific Advisory Groups (SAGs) and Ad-hoc Expert Groups (AHEG)

No topics

6. Patients, Healthcare Professionals and Consumers

6.1. Patients and Consumers Working Party (PCWP) Healthcare Professionals Working Party (HCPWP)

PCWP: Co-chair: Juan Garcia Burgos (EMA)

HCPWP: Co-chair: Juan Garcia Burgos (EMA)

6.1.1. Early contact with patient/consumer organisations at time of MAA

In order to make engagement practices more efficient and enhance timely participation, a proposal to establish contact with relevant patient/consumer organisations at the start of new medicines assessment was launched and was successfully completed. This methodology enables patients to share aspects such as quality of life, treatment options and unmet medical needs with CHMP rapporteurs prior to the Day 80 assessment report so that the CHMP is well-aware of all aspects from the beginning. This is also expected to facilitate further interactions with patients as the procedure progresses. Upon successful completion of the pilot, it was agreed to extend to non-orphan medicines and to also consult healthcare professional organisations (see outcome report).

CHMP: Fatima Ventura and Maria Concepcion Prieto Yerro

Action: For discussion

7. Harmonisation and consistency groups

7.1. International Council on Harmonisation (ICH)

7.1.1. ICH S12

ICH S12 Guideline on "Nonclinical Biodistribution Considerations for Gene Therapy Products", Step 4.

Action: For adoption

7.1.2. ICH M7

ICH M7 Guideline on Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk – addendum.

Action: For adoption

7.2. Guideline Consistency Group (GCG)

No topics

7.3. Summary of product characteristics Advisory Group

No topics

8. Joint groups and collaboration with other Scientific committees

8.1. Joint CHMP/CVMP/CMDh/CMDv Working Group on Active Substance Master File Procedures (ASMF WG)

No topics

8.2. Collaboration with other Scientific committees

8.2.1. PRAC report to CHMP

Chair: Sabine Straus

Summary of recommendations and advice of PRAC meeting held on 13-16 March 2023.

Action: For information

9. Regulatory/Organisational matters

9.1. Regulatory Issues/new legislation

No topics

9.2. CHMP organisation/templates

9.2.1. CHMP learnings

Collection, discussion and recording of CHMP learnings.

CHMP: Outi Mäki-Ikola

Action: For discussion

9.2.2. New changes to the multinational team (MNAT) process

Extension to phase II for post-authorisation procedures and pilot initiative on external expert involvement.

Action: For information

9.2.3. CHMP AR template – Revamp Project

Presentation on the new CHMP AR template

Action: For discussion

9.2.4. Companion Diagnostics (CDx)

Update from the Companion Diagnostics Expert group meeting (10 March 2023).

IVD wording in SmPC.

Action: For information

9.2.5. Proposal for a CHMP oncology preparatory meeting (ONCO-PREP) pilot

Proposal for a pilot preparatory meeting to highlight upcoming oncology applications. The aim of the ONCO-PREP meetings is to facilitate preparation for the CHMP plenary discussion, facilitating identification of positions, and any potential controversial issues, including those that require specific secretariate support in advance of the plenary discussion.

CHMP: Harald Enzmann

Action: For information

10. Product development support

10.1. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi, Vice-Chair: Pierre Demolis

10.1.1. Appointment of CHMP peer review for SA

Action: For information

10.1.2. Agenda and Table of Decisions

- Agenda from 13-16 March 2023 meeting held by Webex
- Draft Table of Decisions from 13-16 March 2023 meeting held by Webex

Action: For information

10.2. Innovation Task Force

10.2.1. ITF meeting

Meeting date: 27 March 2023

Action: For adoption

10.2.2. ITF meeting

Meeting date: 31 March 2023

Action: For adoption

10.2.3. ITF meeting

Meeting date: 04 April 2023

Action: For adoption

10.2.4. ITF meeting

Meeting date: 05 April 2023 or 25 April 2023 (tbd)

Action: For adoption

11. Product related topics

11.1. Preview CHMP Plenary

CHMP: Harald Enzmann

Action: For information

11.2. COVID-19 vaccine (recombinant, adjuvanted) - EMEA/H/C/005998

active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older;

List of Questions adopted on 15.12.2022.

The Applicant has requested a clock-stop extension.

Action: For discussion

12. Any Other Business

12.1. Rapporteurships

Update.

Action: For information

12.2. Update on the proof-of-concept raw data pilot

The second regulatory procedure for the clinical trials raw data pilot has been selected. It is a biosimilar application with an endocrinology indication.

Action: For information